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ABSTRACT: Gram-negative bacteria possess numerous defenses against antibiotics, due to 
the intrinsic permeability barrier of their outer membrane, explaining the recalcitrance of 
some common and life-threatening infections. We report the formulation of a new drug, 
PPA148, which shows promising activity against all Gram-negative bacteria included in 
the ESKAPEE pathogens. PPA148 was solubilized by inclusion complexation with 
cyclodextrin followed by encapsulation in liposomes. The complex and liposomal 
formulation presented increased activity against E. coli compared to the pure drug when 
assessed with the Kirby Bauer assay. The novel formulation containing 1 μg PPA148 
reached similar efficacy levels equivalent to those of 30 μg pure rifampicin. A range of 
biophysical techniques was used to explore the mechanism of drug uptake. Langmuir 
trough (LT) and neutron reflectivity (NR) techniques were employed to monitor the 
interaction between the drug and the formulation with model membranes. We found 
evidence for fluidosome fusion with the model Gram-negative outer membrane and for 
cyclodextrins acting as inner membrane permeation enhancers without presenting intrinsic 
antimicrobial activity. An antibiotic-in-cyclodextrin-in-liposomes (ACL) formulation was 
developed, which targets both the bacterial OM and IM, and offers promise as a means to 
breach the Gram-negative cell envelope. 
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ABBREVIATIONS: OM: Outer membrane, IM: Inner membrane, LPS: Lipopolysaccharide, 
PBD: pyrrolobenzodiazepine, MIC: Minimum inhibitory concentration, CD: Cyclodextrin, 
RAMEB: Randomly methylated cyclodextrin, HPβCD: Hydroxy propyl β cyclodextrin, DIMEB: 
heptakis (2,6-di-O-methyl)-β-cyclodextrin, E. coli: Escherichia coli , DLS: Dynamic light 
scattering, DCR: Derived Count Rate, LT: Langmuir trough, LB: Langmuir-Blodget, LS: 
Langmuir-Schaefer, NR: Neutron reflectivity, ACL: Antibiotic in cyclodextrin in liposomes, Tm: 
Phase transition temperature 
 
1 INTRODUCTION 
The Gram-negative bacterial cell envelope consists of a double-membrane and peptidoglycan 
layer, which provide intrinsic protection against the uptake of antibiotics, due to the presence of 
lipopolysaccharide (LPS) in the outer membrane (OM) and envelope-spanning efflux pumps (1–
4). Inter-species horizontal gene transfer between Gram-negatives has also led to the rapid 
proliferation of multi- or pan-drug resistance amongst these bacteria, and led to their being listed 
as a critical priority for antimicrobials research by WHO (1,5). This has attracted a great deal of 
interest in research to develop novel classes and variants of antibiotics (6,7), the activity of which 
may be augmented by formulation approaches aimed at increasing OM permeability and inhibiting 
efflux (8).  
This study focuses on a novel antimicrobial agent, PPA148, belonging to the 
pyrrolobenzodiazepine (PBD) group of anticancer and antimicrobial drugs (Figure 1 and 
Supporting Information Table S1). PBDs are naturally occurring sequence-specific DNA minor 
groove binding agents produced by Streptomyces bacteria which have been evaluated as potential 
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antibacterial agents in recent years (9–11). PBDs have shown promising activity against Gram-
negative bacteria amongst the so-called ESKAPEEs, a group of pathogens of major clinical 
interest, in particular Acinetobacter baumannii and Klebsiella Pneumoniae (with MICs < 2 μg/ml 
in each case) (12). PPA148 is a large, non-ionic, poorly water-soluble drug, whose bactericidal 
activity is attributed to the inhibition of bacterial DNA gyrase, thus disrupting chromosomal 
replication and leading to cell death. Microbiological evaluation of PPA148 against Pseudomonas 
aeruginosa showed that the compound was most effective in the presence of efflux pump inhibitors 
or membrane permeabilizers, highlighting that PPA148 may be subject to efflux and thus exhibits 
low permeability into these bacterial cells (12).  
 
Figure 1. Chemical structure of PPA148 (MW = 698.2 g/mol). ChemDraw software was used to 
estimate the physicochemical properties, which address a highly hydrophobic molecule with logP 
of 0.76 and logS of -7.5.  
Improving the solubility of PP148 is a necessary first step towards developing a formulation for 
pulmonary delivery to increase its efficacy. For this purpose, we have investigated the use of 
cyclodextrins, since they have been used widely as solubilizing agents and can encapsulate a wide 
range of lipophilic molecules through the formation of inclusion complexes (13). β-cyclodextrin 
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and its derivatives in particular (such as  hydroxypropyl- and randomly methylated- βCD) have 
been reported not only to enhance the solubility of poorly soluble drugs but also to increase their 
internalization into cells and improve their biological activity against Gram-negative bacteria (14–
16). For instance, the stability and bactericidal action of antibiotics such as meropenem have been 
enhanced by inclusion complex formation with native βCD (15). Complexation of rifampicin, 
tobramycin and gentamicin with hydroxypropyl- βCD (HPβCD) and randomly methylated βCD 
(RAMEB) were shown to improve the drugs’ biological activity and to eliminate toxicity (16). 
EMA has reported that HPβCD and RAMEB increase the nasal and pulmonary drug permeability 
and are safe for nasal administration in concentrations below 10% (17). Drug/CD complexes are 
in dynamic equilibrium with free drug and free CD molecules and dissociation might occur after 
administration to the lungs, which affects drug bioavailability. Dissociation of moderately weak 
inclusion complexes (binding constant below 104 M-1) might be a result of simple dissolution at 
the site of administration and/or of competitive inclusion effects due to higher affinity of CD 
towards proteins or lung surfactant, such as cholesterol (18,19). In order to reduce this risk of 
dissociation, liposomes were used as a carrier of the PPA148/CD complex. The resultant 
antibiotic-in-cyclodextrin-in-liposome (ACL) formulation (20) combines the properties of 
cyclodextrins as solubilizing agents and DPPC/DMPG [18:1] fluidosomes as liposomal carriers 
with the potential to fuse with the Gram-negative OM and thus improve drug permeability and 
circumvent efflux mechanisms  (21,22). Fluidosomes are unlikely to fuse into human pulmonary 
cells whereas they can fuse into bacterial membranes (23), which could provide specificity to the 
proposed ACL formulation. 
Since both cyclodextrins and fluidosomes have the potential individually to enhance the 
antimicrobial efficacy of the ACL formulation, the activities of the different components were 
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compared with that of pure PPA148, and the possible physical envelope-breaching mechanisms 
underlying ACL action were explored using a range of interfacial biophysical techniques. These 
included an assessment of membrane binding of various formulation components, using adsorption 
isotherms on lipid monolayers at the air/liquid interface, and neutron reflectivity on a supported 
asymmetric Gram-negative model OM to gain molecular-level structural insight into its interaction 
with fluidosomes, and further to determine the feasibility of a putative fusion mechanism. The 
biophysical investigation was carried out alongside microbiological assays, which compared the 
efficacy of PPA148 with that of rifampicin.  
While there have been reports of antibiotics solubilized by either inclusion complexes with CDs, 
or encapsulated in liposomes, we are not aware of any published work on antibiotics formulated 
in ACL. This study constitutes the first formulation approach for the antimicrobial agent PPA148 
as well as the first report of the biophysical characterization and efficacy assessment of the novel 
ACL formulation applied to PPA148. 
2 MATERIALS 
Drugs: PPA148 (Mw = 698.25 g/mol, with an estimated clogP of 2.09 and logP of 0.76) was 
custom synthesized in the Institute of Pharmacy at King’s College London (12,24). Rifampicin 
(purity: 97.1%) was purchased form Sigma-Aldrich, UK. Lipids: Phospholipids 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC, 16:0 PC), 1,2-dipalmitoyl-d62-sn-glycero-3-phosphocholine 
(d62DPPC, 16:0 PC-d62) and 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol, sodium salt (DMPG, 
14:0 PG) were supplied by Avanti Polar Lipids (Alabama, USA). Rc LPS from Escherichia coli 
J5 (purity: protein 1.4%, nucleic acid 0.340%, phosphate 7.3%, Kdo 5.9%), Ra LPS from E. coli 
EH100 and Re Lipid A from Salmonella minnesota R595 containing ≤0.3% proteins were all 
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obtained from Sigma-Aldrich, UK. and were used without further purification. Cyclodextrins: 
Hydroxypropyl- β-cyclodextrin (HPβCD), randomly methylated β-cyclodextrin (RAMEB) and 
heptakis (2,6-di-O-methyl)-β-cyclodextrin (DIMEB) were purchased from Sigma-Aldrich, UK. 
Solvents: Chloroform (CHCl3), dimethyl sulfoxide (DMSO), deuterium oxide (D2O), %) were 
purchased from Sigma-Aldrich, UK. Ultrapure water with a specific resistivity of 18.2 MΩ·cm 
was produced by a Purelab Ultra machine from ELGA Process Water (Marlow, UK). Salts for 
buffers: magnesium sulfate (MgSO4) was purchased from Sigma-Aldrich, UK, and used at the 
drug extraction process. Sodium chloride (NaCl), and magnesium chloride (MgCl2) were supplied 
by Sigma-Aldrich, UK, and were used in the monolayer studies. HEPES (>=99.5%) and calcium 
chloride (CaCl2) were purchased from Sigma-Aldrich, UK, and were used for liposome 
preparation and neutron reflectivity measurements. Microbiology: Blank, rifampicin (30 μg) and 
vancomycin (30 μg) susceptibility disks, agar powder and Muller Hinton broth for microbiology 
were purchased from Oxoid (UK). Escherichia coli bacteria DH5α were obtained from Invitrogen 
Life Science Technology (Thermo Fisher Scientific, UK).  
3 METHODS 
3.1 Formulation development 
3.1.1 Aggregation of PPA148 by Light Scattering and turbidimetry 
The aggregation of the drug and its solubility in aqueous media with and without cyclodextrins, 
were evaluated using both light scattering and turbidimetry. A stock solution of PPA148 (5 mM) 
in DCM was used to produce a range of concentrations (0 - 160 μg/ml) in water, and in the presence 
and absence of 1% HPβCD, by evaporation of DCM.  Samples were left under mild stirring for 7 
days. Dynamic light scattering (DLS) measurements were performed at 25C on a Malvern 
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Zetasizer (Nano-ZS, Malvern Instruments, UK) with a laser of wavelength 623.8 nm and 
backscatter detection angle of 173°.  The derived count rate (DCR) was recorded and its 
normalized form plotted against drug concentration. The same samples were also assessed by 
turbidimetry, using a UV/Vis spectrophotometer (Lamda 2, Perkin Elmer, UK) at a wavelength of 
620 nm. 
3.1.2 Thermodynamic solubility of PPA148 by UV spectroscopy  
An excess of PPA148 (1 mg) was added to deionized water and 20 mM HEPES, 2 mM CaCl2, 145 
mM NaCl (pH =7.2) buffer (1 mL) in the presence and absence of 1% HPβCD and 1% RAMEB. 
The samples were kept under mild stirring (290 rpm) for 7 days. After incubation, samples were 
centrifuged (5 min at 10,000 rpm) and the supernatant was freeze-dried overnight and resuspended 
in ethanol/water (volume ratio of 4:1). The saturated concentration was assayed by UV/Vis 
spectroscopy. The UV spectrum of PPA148 was recorded on a Lamda 2 spectrophotometer (Perkin 
Elmer, UK), at 25˚C using a quartz cuvette (Hellma 114-QS). Absorbance spectra were recorded 
between 200-550 nm, using a slit width of 2 nm and scan speed of 60 nm/min.  
The linearity of this method was determined by analyzing the solutions of PA148 in the range of 
2-200 μg/mL. For quantification purposes, the Limits of Detection (LOD) and Quantification 
(LOQ) were established by regression analysis of the linear region of the calibration curve. Both 
values were calculated using the standard error of the mean (se) and slope (S) taken from the 








     (2) 
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3.1.3 Quantification of drug/cyclodextrin binding constant by fluorescence spectroscopy 
The binding constant of PPA148 for cyclodextrins (HPβCD and RAMEB) was measured by 
fluorescence spectroscopy, following established methods (25). Specific volumes of either 
PPA148 in DCM, or rifampicin in ethanol were transferred into separate vials and the solvent 
evaporated. Two types of modified β-cyclodextrins were used: HPβCD and RAMEB and their 
solutions (0 - 30%) in HEPES (20 mM) buffered saline, pH 7.2 were then added to achieve a final 
drug concentration of 10 μg/mL. The samples were left under mild stirring overnight.  
The fluorescence intensity from PPA148 was measured with a Luminescence spectrometer LS 50 
B (Perkin Elmer, UK), and was conducted with an excitation wavelength of 300 nm, and an 
emission wavelength scan range of 340-530 nm, with emission/excitation slit widths of 5 nm. The 
fluorescence intensity of the drug was plotted as a function of concentration. The binding constant 





  (3) 
𝐾2 =  𝑘1 × 𝑘2    (4) 
where 𝐼0, 𝐼1 and 𝐼2 are the experimental fluorescence intensity from the drug in the absence of 
cyclodextrin, at the first binding site and the second binding site with the drug, respectively. The 
𝐼2 value corresponds to the fluorescence value at the plateau of the curve. For a 1:2 drug/CD 
complex, the binding constants of the drug with the first and second CD unit, i.e. 𝑘1 𝑎𝑛𝑑 𝑘2 
respectively, were determined by fitting the data with equation 3. The binding constant of a 1:2 
drug/CD complex is given by equation 4. 
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A non-linear least squares method was used to fit the experimental results to Equation 3. The 
differences between the calculated fluorescence and the experimentally derived data were 
minimized by varying the values of the binding constant (the iterative approach of Nelder–Mead) 
using the Microsoft Excel Solver function (27). The binding constant of a 1:2 complex is presented 
as the mean of three batches. 
3.1.4 Stoichiometry of the drug/DIMEB complex by 1H NMR: Job’s Plot  
The stoichiometry of the drug/DIMEB complex was studied by liquid state 1-dimensional (1D) 
proton (1H) NMR spectroscopy. 1H NMR spectroscopy was carried out on an AscendTM 400 
MHz spectrometer equipped with a SampleXpress autosampler system (Bruker, UK). The 
parameters included sweep width of 8012.82 Hz, acquisition time of 4.09 s and 16 scans and were 
collected with a zg30 pulse program.  
The applied method is known as the continuous method variation or Job’s plot (28). DIMEB, 
which is methylated in two positions of each glucose unit, was used as it provides a high resolution 
spectrum from which all the protons can be assigned, unlike RAMEB and HPβCD, which are 
randomly substituted and therefore lead to spectra with broad peaks (29). Equimolar solutions 
(1mM) of PPA148 and DIMEB in D2O were prepared and mixed in varying volume fractions 
whilst keeping the total concentration constant (1 mM). PPA148 and DIMEB solutions were mixed 
in volume fractions ranging from 0 to 1 mL with an increment of 0.1 mL. The inclusion of PPA148 
into the DIMEB cavity is detected by changes in the chemical shift observed with selected protons 
of the cyclodextrin. The resonances of the DIMEB interior hydrogens, i.e. in positions 3 (H3) and 
5 (H5), were observed as a triplet at 3.90, 3.92 and 3.94 ppm and as a doublet at 3.84 and 3.86 
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ppm, respectively. The chemical shift of the exterior proton in position 1 (H1) was presented as a 
doublet at 5.19 and 5.18 ppm. (30) (31).  
The stoichiometry of the complex was obtained by normalizing the variations of the chemical 
shifts of the host by its mole fraction (XCD) and plotting them against cyclodextrin mole fraction 
(XCD) (32). The shift of the DIMEB hydrogen resonance depends on the mole fraction of pure 
drug, pure DIMEB and drug/DIMEB complexes. A 1:1 complex presents a maximum signal at 0.5 
CD mole fraction.  
3.1.5 Preparation of drug-cyclodextrin inclusion complexes 
A 1:2 complex of drug and RAMEB was used for its encapsulation into liposomes. Drug and 
cyclodextrin were mixed in a 1:2 molar ratio in HEPES buffered saline at pH 7.2. The mixture was 
continuously stirred (190 rpm) for 24 hours in order to ensure equilibrium and complex formation.  
3.1.6 ACL preparation 
Fluidosomes consisting of DPPC/DMPG in an 18:1 molar ratio were prepared by the thin film 
solvation method (33). The mixture of lipids (20 mg total) was dissolved in 1 mL of chloroform 
in a round-bottomed flask and bath sonicated (Fisherbrand®, FB11203, Fisher Scientific, UK) at 
25°C for approximately 1 min to achieve a visibly clear solution. The solvent was evaporated using 
a rotary evaporator (Rotavapor® RII, Büchi, Switzerland) attached to a vacuum pump (KNF Lab, 
UK). The temperature of the water bath was set to 40°C and the rotation speed to approximately 
190 rpm. The resulting thin lipid film was kept under reduced pressure in a Pyrex vacuum 
desiccator for 12 h to remove any traces of organic solvent. The lipid film was then solvated by 
adding 4 mL of 20 mM HEPES buffered saline pH 7.2 (145 mM NaCl and 10 mM CaCl2) 
containing the previously prepared inclusion complexes under vigorous stirring and bath 
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sonication (Fisherbrand®, FB11203, Fisher Scientific, UK) at 40°C to facilitate vesicle formation. 
The lipid suspension was dipped into an ice bath (4°C) for 1 min and then placed in the water bath 
(40°C) for another minute. This temperature changing sequence was repeated 5 times followed by 
a 1 h annealing period at 4°C before using them for size reduction.  
Size reduction of ACLs was carried out by extrusion, to produce homogeneous dispersions of 
unilamellar vesicles. A 1 mL ACL dispersion was loaded into a gas-tight syringe in a mini-extruder 
(Avanti Polar Lipids, AL, USA) thermostatically heated to 55°C and manually extruded through 
a 0.1 μm pore polycarbonate membrane 11 times. The extruded ACLs were kept at 4°C and were 
extruded again under the same experimental set up after 12 hours. The double extruded ACLs were 
stored at 4°C before measuring their size using PCS. All samples were prepared and measured in 
triplicate. 
Size exclusion chromatography was used to separate the liposomes from the unentrapped drug/CD 
complexes. A Sephadex™ G-25 PD-10 column (GE Healthcare, UK) was equilibrated with 15 mL 
of 20 mM HEPES buffered saline, pH 7.2. Each liposome mixture (1 mL) was allowed to penetrate 
the gel entirely and the eluted volume was discarded. Then, aliquots of HEPES buffered saline (1 
mL) were added to the column sequentially (8 times) to elute various fractions which were 
collected separately. Each fraction was characterized for its hydrodynamic diameter, derived count 
rate, lipid and drug concentration to determine which aliquot contained the majority of the loaded 
liposomes. The determination of lipid concentration was achieved using the colorimetric Stewart 
assay (34). 
Drug quantification was carried out using UV/Vis spectroscopy to determine the encapsulation 
efficiency (EE) and the drug loading (DL) of liposomes. PPA148 was extracted from all 8 aliquots 
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collected after size exclusion chromatography. Each aliquot was washed with DCM and the 
organic phase was collected, dried with magnesium sulfate (MgSO4) and evaporated under vacuum 
(Rotavapor® RII, Büchi®, Switzerland and KNF Lab vacuum pump, UK). The resulting dry 
sample was re-suspended in ethanol/water (80:20) and the unknown drug concentration was 
calculated by interpolating from a linear calibration curve, which was determined under the same 
experimental conditions. The area under the curve (AUC) of all samples was used for drug 
quantification (35) and calculated using GraphPad Prism 7.03 software (GraphPad software Inc., 
USA). The test samples were run in quadruplet replicates and the calibration curve samples per 
concentration were run in triplicate. The Encapsulation Efficiency (EE) and Drug Loading (DL) 








× 100%   (6) 
where 𝐶𝑢 is the un-entrapped drug concentration, 𝐶𝐿 and 𝐶𝑇 are the concentration of lipids and 
drug added into the liposome system, respectively. 
3.1.7 Kirby Bauer assay to assess the efficacy of PPA148-in-RAMEB-in-fluidosomes 
The Kirby Bauer method, also known as the disk diffusion assay, is commonly used for testing the 
susceptibility of bacteria to drugs and chemicals (36,37). E. coli was cultured on a Mueller-Hinton 
(MH) agar (21 g/L MH broth and 17 g/L agar) from a gel-bead for 24 h at 37˚C. Bacterial colonies 
were transferred in MH broth until the optical density (OD) of the bacterial suspension reached 1 
(~8108 cells/mL) at 600 nm. The OD was measured using a single beam JENWAY 6300 Visible 
Spectrophotometer (Staffordshire, UK) with resolution of 1 nm and spectral bandwidth of 8 nm. 
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To stop bacterial growth, 1 mL of the suspension was centrifuged at 10,000G for 5 min and the 
bacterial pellets were re-dispersed in sterile physiological saline (0.9% NaCl). An aliquot of this 
suspension (100 μL) was spread onto an MH agar plate, and filter disks impregnated with antibiotic 
were placed on top. The plates were incubated for 24 h at 37˚C, after which the diameter of the 
inhibition zones surrounding the antibiotic disks, was measured.  
Commercially available disks for rifampicin (30 μg) and vancomycin (30 μg) were used as positive 
and negative controls respectively, based on their differing abilities to inhibit Gram-negative 
bacterial growth. However, the filter disk for the novel antibiotic (PPA148 1 μg) as well as for the 
complex and ACF, were prepared in-house. All stock solutions (PPA148 5 mM in DCM, 1:2 
complex (0.5 mg/mL), 5% RAMEB and ACF 0.5 mg/ml) were sterilized using a UV lamp 
(Spectroline®, ENF-24C/FE, Spectronics corporation, Westbury, New York, USA) at 254 nm 
(ultraviolet germicidal irradiation). A volume equivalent to PPA148 1 μg was placed on the paper 
disk plate, absorbed and evaporated under reduced pressure. To validate the preparation method 
of the in-house disks, disks containing 30 μg of rifampicin were prepared using the same method 
and the results were compared to those of the commercially available disks. All samples were 
prepared and tested 10 times. 
3.2 Mechanistic investigation 
3.2.1 Gibbs isotherms of drug-monolayer interactions 
Gibbs isotherms were used to assess the interaction of PPA148, rifampicin, cyclodextrins and 
fluidosomes with biomimetic lipid monolayers (DPPC/DPPG (3:1), Lipid A and J5 LPS). DPPC 
was chosen instead of PE lipids, which are one of the predominant lipids in bacterial cell envelope 
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(38,39), to avoid artefacts arising from the tendency of PE to form negatively curved interfaces 
(40,41). The mixture DPPC/DPPG keeps the interface planar.  
A 50 mm diameter perfluoroalkoxy (PFA) petri dish (Saint-Gobain Performance Plastics) with a 
20 mL capacity was placed over a magnetic stirring plate and filled with a filtered 1 mM MgCl2 
solution or 20 mM HEPES buffered saline containing 2 mM CaCl2 (pH 7.2) through a 0.45 m 
Minisart® filter, under mild stirring. A Wilhelmy plate (Whatman, grade 1, chromatographic 
paper) connected to a calibrated NIMA PS4 (0-240 mN/m range, 0.1 mN/m resolution) pressure 
microbalance was submerged into the subphase. A syringe containing 100 μL PPA148 solution in 
DMSO or one of the other samples in water was placed with its hypodermic needle (gauge 25G, 
BD biosciences UK, Oxford, UK) penetrating into the subphase. Any alteration in surface pressure 
produced upon injection of the sample, as molecules adsorbed or desorbed at the air/liquid 
interface were recorded by the microbalance. Prior to subphase injection, a lipid solution in 
chloroform (1 mg/mL) was spread dropwise at the air/water interface until the surface pressure 
reached 30-35 mN/m (the lateral pressure in biomembranes) (42), while stirring the subphase with 
a 4.5×15 mm magnetic stirrer bar set at its minimum speed to avoid variation of pressure greater 
than 0.2 mN/m. A period of 40 to 60 min was allowed for the solvent to evaporate and for the 
monolayer to reach equilibrium (stabilization of the surface pressure, Π𝑖𝑛𝑖𝑡𝑖𝑎𝑙). Drug solution (0.1 
mL) was then injected below the lipid monolayer to produce a final concentration in the trough of 
20 g/mL. Changes in surface pressure were recorded until a new pseudo-plateau was reached 
(Π𝑚𝑎𝑥).  
The rate of change in surface pressure (ΔΠ) was plotted against time and the binding isotherms 
produced were fitted with a sigmoidal 3-parameter Hill plot using GraphPad, Prism 7 (GraphPad 








    (7) 
where ΔΠ𝑚𝑎𝑥is the maximum difference in surface pressure (ΔΠ𝑚𝑎𝑥 = Π𝑚𝑎𝑥 − Π𝑖𝑛𝑖𝑡𝑖𝑎𝑙), h is the 
hill coefficient, and  t50% is the time needed to achieve half ΔΠ𝑚𝑎𝑥. The Hill coefficient describes 
the overall growth or decrease rate of the curve and is a measure of how quickly the curve moves 
from the lower asymptote to the upper asymptote or the opposite. Large h (steep curve) describes 
a fast change in surface pressure and high affinity of the drug towards the air/liquid interface. All 
samples were prepared and tested in triplicate. 
3.2.2 Interaction of fluidosomes with a model Gram-negative outer membrane assessed by 
Neutron reflectivity 
3.2.3 Solid-supported asymmetric DPPC and LPS bilayer (model OM) deposition 
The lipid components of model Gram-negative bacterial membranes were deposited onto the 
piranha-cleaned polished oxidized surface of 50×80×20 mm single silicon crystals (Crystran, 
Poole, UK.), using a Langmuir trough (KSV-NIMA, Biolin Scientific, Finland). The Langmuir-
Blodget (LB) technique was used to deposit the inner leaflet of the membrane (d62DPPC) on the 
50×80 mm polished surface of the crystal, and Langmuir-Schaefer (LS) deposition used for the 
outer leaflet of the membrane (hydrogenous E. coli EH100 LPS or hLPS), following the method 
of Clifton et al. (43,44). 
Three isotherm cycles were conducted prior to deposition to examine the stability of the 
monolayers (see Supporting Information, Figure S9). For the LB deposition, the silicon block was 
submerged into the ultrapure non-buffered water subphase, which contained 5 mM CaCl2 and was 
cooled to 10°C to improve interfacial coverage. A solution of d62DPPC in chloroform was 
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deposited dropwise on the subphase surface and compressed slowly to a constant surface pressure 
of 38 mN/m. The silicon crystal was lifted through the air-water interface at a speed of 4 mm/min 
while keeping the surface pressure constant at 38 mN/m. The silicon block was therefore covered 
with a homogeneous d-DPPC monolayer, having the headgroup towards the silicon block and the 
hydrophobic tails facing the environment.  
The Langmuir trough was then cleaned and the air-liquid interfacial monolayer of hLPS (2.5 
mg/mL) was deposited (from 60% chloroform, 39% methanol and 1% water v/v) on to the same 
composition clean non-buffered interface, cooled at 10°C, with a surface pressure of 38 mN/m. 
The LS deposition was achieved by securing the previously covered silicon block into a holder 
above and parallel with the interface with the previously deposited DPPC acyl chains pointing 
downward, toward the interface. The silicon block was lowered at a speed of 3 mm/min through 
the interface in order to allow the lipid monolayer on the block to match the LPS monolayer on 
the subphase via the hydrophobic chains, producing a solid supported asymmetric bilayer (model 
OM) (43). The block was then allowed to continue moving downwards until the bottom of the 
trough was reached where a customized PTFE sample cell was placed. The sample cell and silicon 
block were secured in a custom-made metal holder to ensure the bilayer was fully contained and 
sealed inside the small water chamber of the sample cell, whose total volume was 3 mL. 
3.2.4 Neutron reflectometry measurements  
Specular neutron reflectometry (NR) measurements were conducted using the INTER 
reflectometer at the ISIS neutron source, Rutherford Appleton Laboratory (STFC, Oxfordshire, 
UK), using neutron wavelengths from 1.5 to 16 Å. The reflected intensity was measured at two 
incident angles of 0.7° and 2.3° as a function of the momentum transfer Q (𝑄 =
4𝜋 sin 𝜃
𝜆
, where λ 
18 
 
is the wavelength and θ is the incident angle). The purpose-built flow cell of the silicon-liquid 
interface (described above) was placed on an anti-vibration sample stage and the inlet of the cell 
was connected to a L7100 HPLC pump (Merck, Hitachi, Germany).  
One solid-supported model OM was used in this experiment and NR was carried out at 38°C under 
two different conditions, i.e. before and after the challenge with liposomes. Once the data 
collection was completed for the unchallenged model OM, fluidosomes (0.1 mg/mL in 20 mM 
HEPES buffered saline containing 2 mM CaCl2 pH 7.2) were injected into the sample cell via the 
HPLC pump at a 1.5mL/min flow rate and allowed to incubate for 1 h. The excess fluidosomes 
were flushed out of the cell chamber at a rate of 1.5mL/min before data acquisition, in order to 
measure the possible structural changes caused by their interaction with the model OM. 
Both experimental treatments of the model OM were examined under three different isotopic 
contrast conditions, i.e. 100% H2O, 100% D2O and silicon matched water or SMW (38% D2O, 
62% H2O), to highlight the different components of the bilayer structure. All isotopic solutions 
contained 20 mM HEPES, 145 mM NaCl and 5mM CaCl2 to maintain the asymmetry of the model 
OM. The HPLC pump facilitated automated exchange of the different contrast solvents within the 
cell (3 mL) at a flow rate of 1.5 mL/min. 
3.2.5 NR data fitting and Statistical analysis 
RaScal software was used to fit the experimental data on Born and Wolf’s optical matrix formalism 
to convert the raw reflectivity data into a real space description of the scattering length density 
across the interface (45,46). The interface is described as a series of slabs, each one representing 
different compartments of the solid-supported model OM, i.e. the silicon oxide layer of the crystal, 
inner headgroup, inner tails, outer tails and outer headgroup layer. Bayesian Markov Chain Monte 
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Carlo (MCMC) statistics with 95% confidence interval were applied to estimate the parameters 
most likely to produce the experimental reflectivity data observed given the already known layered 
model (47,48). The parameters of interest were the scattering length density (SLD), thickness, 
roughness and hydration state of each layer. In addition to the model parameters, the backgrounds, 
scale factors and instrument resolutions were also fitted. The MCMC was carried out for thousands 
of iterations and Chi squared (Χ2) was used to adjust the fit of the parameters by reducing the 
difference between the known layered model and the experimental reflectivity data.  For all sets 
of data, the simplest (least number of layers) model was selected based on the overall chi-squared. 
Due to the complexity of the five-layered model, a skewed data distribution was assumed and thus 
the lower and upper values of each parameter were presented instead of a standard deviation.  
The three contrasts used for each experimental treatment produced three reflectivity profiles which 
were simultaneously fitted. The difference in SLD of the d62DPPC and hLPS tails in the three 
solvent contrasts was used to determine the volume fraction of the water in each leaflet of the 
model OM. In the tail region of d62DPPC and hLPS, neither lipid tails possess labile hydrogens 
and, therefore, do not undergo changes in SLD (ρ). The calculated volume fraction of water and 
the SLD experimental values of the of d62DPPC tails, LPS tails were measured, the volume fraction 
of the DPPC tails can be calculated as described in detail by Clifton et al.(2013) (43). 
The asymmetry of the model OM was examined by calculating the volume fraction of water and 




4.1 Aggregation and thermodynamic solubility of the drug 
Solubility studies with UV-Vis spectroscopy revealed that for concentrations between 1-15 µg/mL, 
the absorbance of PPA148 in water is proportional to its concentration, but it deviates at higher 
concentrations (see Supporting Information, Figure S1), suggesting the presence of molecular 
aggregates. Figure 2 presents the changes in normalized derived count rate (nDCR) against drug 
concentration in water at 25°C; the sharp increase in nDCR reflects the onset of critical aggregation  
(50), which occurs around 20 μg/mL. DLS measurements reveal aggregates of average size 1-18 
µm and a high polydispersity index (0.7) (see Supporting Information, Figure S2). A similar 
aggregation concentration value was obtained with turbidity measurements using UV/Vis 
spectroscopy at 620 nm (Figure 2, Table 1). The scattering of light upon increasing drug 
concentration in water presented a more variable profile, which is an indication of PPA148’s very 
low solubility and high propensity to aggregate in water. Precipitation of the drug in water was 
visually observed at concentrations higher than ~30 μg/mL. In the presence of HPβCD, the 
aggregation limit is shifted to higher concentrations (ca. 50 μg/mL), confirming the capacity of the 




Figure 2. Turbidimetric assay: Effect of 1% HPβCD (7 mM) concentration on the aggregation of 
PPA148 in ultra-pure water (18.2 MΩ·cm) at 25°C using dynamic light scattering (right) and 
UV/Vis spectroscopy (left). The data are presented as normalized derived count rate and 
absorbance at 620 nm against PPA148 concentration in water (top) and 1% HPβCD (bottom). The 
red line is the linear regression fit and the orange lines are the 95% confidence intervals. The 
intersection of the two linear models provides the aggregation concentration. 
The thermodynamic solubility (𝑆0) of PPA148 was investigated in water and HEPES buffer saline 
pH 7.2 by UV spectroscopy at the maximum absorbance of PPA148. RAMEB and HPβCD were 
shown to solubilize PPA148 up to approximately 50 µg/mL in HEPES buffered saline pH 7.2 
(Figure 2, Table 1). 
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Table 1. Solubility and aggregation of PPA148 in the presence and absence of 1% HPβCD (7 mM) 











H2O 30.3  1.8 18.1  4.7 16.3  11.1 
HEPES 55.8  15.9 - - 
HPβCD/H2O - 51.1  2.6 53.9  12.1 
RAMEB/HEPES 90.5  4.4 - - 
4.2 Quantification of drug/cyclodextrin binding constant by fluorescence spectroscopy 
The interaction of PPA148 with cyclodextrins and the binding constant of the inclusion complex 
was investigated using fluorescence spectroscopy. Shifts in the fluorescence drug peak at 422 nm 
for PPA148 are due to inclusion complex formation because the drug is transferred from the polar 
aqueous phase to the less polar CD cavity. The addition of increasing concentrations of 
cyclodextrin (either RAMEB or HPβCD) from 0 to 30 % w/v (0-171 mM for HPβCD and 0-225 
mM for RAMEB) to a fixed concentration of 10 μg/mL PPA148 produces a hyperchromic effect, 
reflecting changes in the environment, in which the whole or part of the drug is included in the 
cavity of HPβCD or RAMEB. The experimental data were fitted using Equation 3 (Figure 3A), 




Figure 3. (A) Binding constant assay of the 1:2 complex between PPA148 (10 μg/mL) with 
RAMEB and HPβCD using fluorescence spectroscopy at 25°C (n = 3). (B) Job’s plot showing the 
1:2 stoichiometry of the PPA148/DIMEB complex in D2O using 
1HNMR spectroscopy. 
4.3 Stoichiometry of the drug/DIMEB complex by 1H NMR: Job’s Plot  
DIMEB was used as a model of methylated -cyclodextrin to measure the stoichiometry of the 
inclusion complex between PPA148 and methylated -cyclodextrins. DIMEB is methylated in two 
specific sites on the CD molecule and thus gives narrow peaks in the 1H NMR spectrum compared 
to the randomly methylated and hydroxy-propylated -cyclodextrins used in the formulation 
(RAMEB and HPβCD). PPA148 was used below its solubility limit (20 μg/mL, or 0.03 mM). As 
a result, the spectra obtained were quite noisy, due to the low concentration, but the chemical shifts 
of the hydrogen at position 5 (H5) were clearly detected (see Supporting Information, Figure S3) 
and show a skewed Job’s plot with a maximum around XCD=0.6 (Figure 3B), reflecting a 1:2 




4.4 Preparation of drug-cyclodextrin inclusion complexes 
Based on the higher affinity of PPA148 for RAMEB (Figure 3A), this cyclodextrin was selected 
for encapsulation in fluidosomes to evaluate the full formulation. The elution profile of loaded 
fluidosomes (DPPC/DMPG in 18/1 molar ratio) is presented in Figure 4A. The derived count rate 
(DCR) profile showed that the majority of fluidosomes eluted in the third fraction (Figure 4A), 
with a size of 129  1 nm (see Supporting Information, Figure S4). The difference between the 
size of the empty (128  2 nm) and PPA148/RAMEB encapsulated fluidosomes was not 
statistically significant (p=0.25).  
A Stewart assay was used to quantify the DPPC content in the eluted fractions of fluidosomes 
because it accounts for 95% of lipids in the mixture (DPPC/DMPG [18/1]) and the colorimetric 
test is not sensitive to phosphatidylglycerol (PG) lipids. The third fraction contained the majority 
of lipids, which agrees with the DCR profile. This fraction held 88  2% of the initial DPPC 
concentration in the fluidosome formulation (19 mg/mL), with a limited lipid loss of 12  2%, as 




Figure 4. (A) Elution pattern of PPA148/RAMEB encapsulated fluidosomes (2.5 mg/mL) in 
HEPES buffered saline (pH=7.2) from the size exclusion column. The derived count rate (DCR) 
profile and DPPC content of fluidosomes in each aliquot were measured to investigate the elution 
profile of loaded liposomes. (B) Drug quantification profile of the eluted fraction from the PD10 
G25 size exclusion chromatography column is presented as a function of the area under the curve 
(AUC). The linear calibration curve is presented in Supporting Information, Figure S5.  
The third fraction contained liposomes and held 77  22% of the initial lipid concentration (20 
mg/mL), with a limited lipid loss of 13  9%, as assessed by the Stewart assay (Equation S1 and 
Equation S2). The sum of lipids in all aliquots presented no overall lipid loss due to the extrusion 
process. The third fraction contained the highest drug content (280  120 μg/mL) (Figure 4B) with 
encapsulation efficiency (EE) of 67  11% and drug loading (DL) of 5  1%. The EE and DL 
values of the DPPC/DMPG liposomes employed in this study were consistent with those 
previously reported using different drugs but similar preparation methods (51,52). The total drug 
concentration (590  113 μg/mL) obtained from the total eluted volume from the Sephadex column 
is in agreement – within experimental error - with the initial drug concentration (500 μg/mL) which 
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was used to hydrate the lipid film. Both empty and RAMEB-encapsulating fluidosomes presented 
good size stability over the 10 weeks (see Supporting Information, Figure S6). 
4.5 Kirby Bauer assay to assess the efficacy of PPA148-in-RAMEB-in-fluidosomes 
The in vitro efficacy of the encapsulated drug/RAMEB complex in liposomes against Gram-
negative bacteria was tested by using the Kirby Bauer assay. Commercially available disks of 
rifampicin (30 μg) and vancomycin (30 μg) were used as positive and negative controls against E. 
coli DH5a, which does not possess any antibiotic resistance genes. The in-house rifampicin disk 
(30 μg) caused inhibition of bacterial growth, in the same way as the commercially available disks, 
and was used as a positive control, while vancomycin did not affect the growth. Rifampicin is 
known to target the DNA-dependent RNA polymerase and passively diffuse through the cell 
envelope (53), and presents similar physicochemical properties with PPA148 (see Supporting 
Information, Table S1).  Vancomycin is known to be effective against Gram-positive bacteria, but 
its activity against Gram-negative bacteria is hindered by its large size and the impermeable 
bacterial OM (54). Disks impregnated with PPA148 (1 μg/mL), rifampicin (1 and 30 μg/mL), 
RAMEB, PPA148/RAMEB complex, empty fluidosomes, and encapsulated fluidosomes with 
PPA148/RAMEB were prepared in-house. In-house rifampicin disks (30 μg/mL) were compared 
with the commercially available disks of the same concentration to validate the preparation method 
and there was no statistically significant difference (P=0.06). Figure 5 shows the inhibition zone 




Figure 5. Kirby-Bauer assay for measuring the growth inhibition of Escherichia coli DH5α. The 
inhibition zone diameter was measured for pure rifampicin (30 μg and 1 μg) and PPA148 (1 μg) 
as a pure substance and as a formulated drug (in a 1% RAMEB complex and incorporated into 0.1 
mg fluidosomes as a complex with 1% RAMEB) after 24 hour incubation at 37°C. Rifampicin and 
vancomycin were used as positive and negative control samples. The asterisks denote the level of 
significance going from lower to higher as follows: 0.1244 (ns), 0.0332 (*), 0.0021 (**), 0.0002 
(***), <0.0001 (****). All samples were tested 12 times. 
A one-way ANOVA test showed that, overall, the groups were significantly different (p<0.0001) 
at 95% confidence interval. The multiple comparison showed a clear picture within each group. 
Empty liposomes and pure cyclodextrin presented zero inhibition zone. There was a statistically 
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significant difference between the free drug, RAMEB/PPA148 complex (p<0.0001) and PPA148-
in-RAMEB-in-liposomes (p=0.0002). The encapsulation of the complex into liposomes did not 
hinder the efficacy of the complex. Indeed, the difference between the means of the drug/CD 
complex alone and those encapsulated within liposomes was not statistically significant (p>0.999). 
Both the complex alone and encapsulated into liposomal vesicles presented better inhibition 
compared to the positive control. 
4.6 Mechanistic study of the partition of the individual formulation components into the 
model bacterial IM and OM  
4.6.1 Interaction with model OM using Gibbs isotherms 
The first step in exploring the mechanism of the formulation was to examine the interaction 
between pure PPA148 or the carrier (fluidosomes) and model bacterial OM, as this is the first and 
most important permeability barrier encountered. R595 Lipid A and Rc LPS J5 monolayers were 
used to investigate the effect of the steric barrier of the OM outer leaflet on PPA148, rifampicin 
and empty fluidosomes. R595 Lipid A constitutes the membrane anchor of LPS and lacks the 
extended polysaccharide chain of the headgroup. After subphase injection of rifampicin to a final 
concentration in the trough of 20 μg/mL, the surface pressure remained constant, reflecting the 
lack of impact on the packing of Lipid A monolayer (Figure 6). PPA148 produced an increase in 
surface pressure of 6.9 ± 0.7 mN/m, reaching a plateau in less than an hour with a high binding 
affinity (Hill slope = 1.3 ± 0.2), thus denoting some interaction between the drug and the 
monolayer (Figure 6). In the presence of Rc LPS J5 monolayers, the increase in surface pressure 
is weaker, showing low efficiency (∆Π𝑚𝑎𝑥 = 3.7 ± 2.1 mN/m), weak binding capacity (Hill slope 
= 3.7 ± 2.6) but a fast rate of binding with 𝑡50% = 0.2 ± 0.1 h (Figure 6). Being a lipophilic drug, 
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PPA148, was expected to adsorb on the air/liquid interface between the lipids as it did on a lipid 
free interface (see Supporting Information, Figure S7), which produced an increase in surface 
pressure of 13.3  1.3 mN/m with 𝑡50% = 0.3 ± 0.2 h.  
 
Figure 6. Representative Gibbs isotherms at 23  1 °C of PPA148 and rifampicin using R595 
Lipid A extracted from Salmonella minnesota and Rc J5 LPS extracted from E. coli monolayers 
and 1 mM MgCl2 as a subphase. Both Lipid A and LPS monolayers were compressed at a surface 
pressure of 30-35 mN/m and the drugs were used at a concentration of 20 μg/mL and the black 
lines are the fitted curves based on the mathematical model. 
The carrier of the drug/CD complex, fluidosomes, were tested on model bacterial OM to 
investigate their mechanism of action. Preliminary results revealed the adsorption of fluidosomes 
on lipid free surface (HEPES buffered saline containing CaCl2) and the R595 Lipid A monolayer. 
In the absence of lipid monolayer, fluidosomes adsorbed on the clean surface, reaching a change 
in surface pressure of 11.0 ± 4.8 mN/m. An increase in surface pressure was also observed after 
injecting fluidosomes below the R595 Lipid A monolayer (∆Π𝑚𝑎𝑥 = 6.3 ± 1.9 mN/m). The speed 
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and affinity towards both lipid free surface and R595 Lipid A monolayers are high and of the same 
magnitude (hill slope of 1.0 ± 0.4 and  0.4 ± 0.3 respectively) (Figure 7). However, fluidosomes 
caused solubilization of Rc J5 LPS monolayer. The surface pressure dropped to -10.4 ± 1.3 mN/m 
within 3 h, which illustrates removal of the lipids from the surface. Precipitation of lipids in the 
subphase was observed visually in the petri dish.  
 
Figure 7. Representative adsorption and Gibbs isotherms at 23  1 °C of 0.1 mg/mL fluidosomes 
using 20 mM HEPES buffered saline containing 2 mM CaCl2 as a subphase (lipid free solution) 
and two different lipid monolayers to mimic the outer leaflet of the OM: Rc J5 LPS extracted from 
E. coli and R 595 Lipid A extracted from Salmonella minnesota. Both Lipid A and LPS monolayers 
were compressed at a surface pressure of 30-35 mN/m. The black line in lipid free and R595 Lipid 
A curves is the fitted curve based on the mathematical model. 
To support the choice of liposomes as carriers, RAMEB and HPCD were tested against LPS and 
Lipid A monolayers (see Supporting Information, Figure S8). The results revealed that the 
solubilizing effect of fluidosomes is stronger than that of cyclodextrins. Particularly, R595 Lipid 
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A or J5 Rc LPS monolayers remained undisturbed by HPCD, while RAMEB induced a weak 
interaction, inducing a decrease in surface pressure to  -5 mN/m. 
4.6.2 Interaction with model IM using Gibbs isotherms 
Cyclodextrins are expected to enhance the permeation of PPA148 through the IM of the bacterial 
membrane (16). Gibb’s isotherms were used to examine the molecular interaction of unformulated 
PPA148 (20 μg/mL) and the pure β-cyclodextrin derivatives, RAMEB and HPβCB, with model 
IM, namely, DPPC/DPPG, in order to mimic the composition of the leaflets of the inner membrane 
of the bacterial cell envelope. Rifampicin was used as a model drug to compare with the novel 
antibiotic. 
DPPC/DPPG mixtures were spread on a small trough surface to form a monolayer. The starting 
surface presure created by the lipid spread was 30-35 mN/m to be equivalent to the lateral pressure 
of the bacterial inner membrane (42). An increase in surface pressure of the monolayer was 
observed, after introducing either of the drugs into the subphase (Figure 8A). PPA148 produced a 
smaller change in surface presure of ~3.7 mN/m, compared to ~15.8 mN/m for rifampicin. A 
different kinetic profile was observed by comparing the Hill slopes of each drug’s Gibbs isotherm, 
i.e. 3.7  2.6 for PPA148 and 0.85  0.25 for rifampicin. PPA148 interacted faster than rifampicin, 
which was not expected, given the similar physicochemical properties of the two drugs (see 




Figure 8. Representative Gibbs isotherms at 23  1 °C of (A) PPA148 and rifampicin and (B) 
RAMEB and HPβCD using DPPC/DPPG (3:1) monolayer and 1 mM MgCl2 as a subphase. The 
drugs were used at a concentration of 20 μg/mL and the cyclodextrin were tested at 1% w/v. The 
black lines in (A) are the fitted curves based on the mathematical model. 
HPβCD and RAMEB showed a solubilization effect on all lipid monolayers by eliciting a negative 
change in their initial surface pressure. DPPC/DPPG (3:1) monolayers underwent a significant loss 
of molecules from the surface when challenged with HPβCD and RAMEB (Figure 8B).  
4.7 Interaction with model OM using neutron reflectivity  
NR was used to further explore the effect of fluidosomes on a model asymmetric bilayer 
representing the Gram-negative OM (Figure 9, Table 2) (44,49,55). The structure of the model 
membrane was characterized at 38°C prior to and after being challenged with the liposomal carrier 
(hydrogenated DPPC/DMPG at a molar ratio of 18:1). The interface was modelled as a series of 
slabs each representing a different layer of the model OM with individual SLD, thickness, 
hydration and roughness (Figure 9A, C). The best-fit of each parameter was obtained from the 
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Bayesian analysis with 95% confidence intervals which is presented in SI (see Supporting 
Information, Table S2, Figure S10). 
 
 
Figure 9. Neutron reflectivity profile (A, C) and model data fits with their scattering length density 












































































































































































(outer leaflet) model membrane before (A, B) and after (C, D) being challenged with 0.1 mg/mL 
hydrogenous fluidosomes (DPPC/DMPG, 18:1) at 38 °C. The sample was measured in three 
isotopic contrasts (D2O, H2O and SMW). The model membrane was fitted into a seven-layered 
mathematical model: Silicon oxide (SiO2), DPPC headgroup (Inner HG), DPPC tails (Inner tails), 
Ra LPS tails (Outer tails) and Ra LPS headgroups (Core), Bridge and Floating bilayer. 
Figure 9A shows the reflectivity and SLD profile of the model outer membrane at 38°C. The NR 
data were fitted to a five-layer model, thereby using the minimal number of layers with which the 
reflectivity data could be fitted. The interference fringe observed in the D2O contrast (Figure 9A) 
indicates the presence of the bilayer. The layers, presented schematically under the fitted SLD 
curves in Figure 9B, are the silicon, silicon oxide, inner d62DPPC headgroups which are 
hydrogenated, inner d62DPPC tails, outer Ra-LPS tails, outer Ra-LPS headgroup (headgroup) and 
bulk solution. The results reveal that a highly asymmetric lipid bilayer was formed on the silicon 
oxide-coated surface of the substrate. 
The fusion mechanism of the fluidosomes with the bacterial membrane was investigated by 
measuring changes in the structure of the fully characterized d62DPPC:h-Ra-LPS bilayer after 
being challenged with 0.1 mg/mL empty fluidosomes for 1 h. Most of the structural changes 
occurring following the addition of fluidosomes involved the tail and outer headgroup regions of 
the lipids. The exposure of the bilayer to fluidosomes resulted in the addition of a fringe in the 
reflectivity profile (Figure 9C), reflecting the presence of two lipid bilayers (Figure 9D), one being 
the OM model and the second being described as a floating bilayer (6th and 7th layer), which is a 





Table 2. Best-fit values of structural parameters (obtained from the Bayesian analysis with 95% 
confidence interval) of the challenged Ra-LPS/DPPC membrane at 38°C derived from fits to the 
neutron reflectivity data shown in Figure 9. The min and max values of each parameter are 
presented in Supporting Information, Table S2. 
Layer 
Asymmetric bilayer at 38 °C 



















































Outer HG/Core 23.1 51.8 21.1 36.0 
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Of the two additional layers formed, the one adjacent to the membrane is a solvent layer (99.94% 
water content) as reflected by its SLD being close to zero, i.e. 0.18×10-6 Å-2, indicating that it is 
composed of mostly hydrogenous material. This solvent layer is described by a thickness of 34.6 
Å and roughness of 3.4 Å. The outermost layer has high water content (75.80%) with an SLD of 
0.03×10-6 Å-2. If the liposomes were intact on the membrane surface, their tail SLD would have 
been similar to the reported SLD of h-DPPC tails (-0.4 ×10-6 Å-2) as published by Clifton and 
coworkers (44). The thickness of the additional layers was found to be 35 and 46 Å for the 6th and 
7th layer, respectively. The 7th layer presented a curved bilayer because its thickness (46 Å) is 2 
Å less than that of a DPPC bilayer (approximately 50-60 Å) in the presence of CaCl2 (41,56,57) .  
The possible structural changes in the model asymmetric OM may infer to a bridge layer and are 




Figure 10. Representation of the possible structural changes in the model OM system after being 
challenged by fluidosomes. 
The volume fraction of water and lipids within the bilayer region show that mixing of the lipids 
occurred as reflected by the lipid composition in the model membrane (Table 3). The contribution 
of hydrogenous phospholipids in the inner leaflet layers, which may be either h-Ra LPS or h-
phospholipids from fluidosomes, increased from 21% before challenge to 35% after adding the 
fluidosomes (Table 3). The hydration of the bilayer decreased from 1.26% to 0.03% and of the 





Table 3. Volume fraction of deuterated DPPC tails (𝝋𝑫𝑷𝑷𝑪), hydrogenous LPS tails (𝝋𝑹𝒂𝑳𝑷𝑺) and 
water (𝝋𝒘𝒂𝒕𝒆𝒓) within the bilayers of Ra-LPS/d-DPPC 38°C before and after the challenge by the 
fluidosomes. Each parameter was obtained with 95% confidence interval which are presented in 
the SI. The min and max values of each parameter are presented in Supporting Information, Table 
S2. 
Layer 
Asymmetric bilayer at 38 °C  
Before challenge After challenge 
𝝋𝑫𝑷𝑷𝑪 𝝋𝑹𝒂𝑳𝑷𝑺 𝝋𝒘𝒂𝒕𝒆𝒓 𝝋𝑫𝑷𝑷𝑪 𝝋𝑹𝒂𝑳𝑷𝑺 𝝋𝒘𝒂𝒕𝒆𝒓 





















Solubility is a major challenge in drug development and pre-formulation science. PPA148 is a 
newly synthesized C8-substituted PBD derivative which presents promising activity against Gram-
negative bacteria. The broader PBD family is known for its poor aqueous solubility due to the high 
number of aromatic rings in their structure, (24) making them soluble in either organic solvents, 
such as chloroform and DCM, or in aqueous solutions containing water-miscible organic solvents, 
such as DMSO and acetonitrile (58). PPA148 is no exception, and possesses a low water solubility 
(30 g/mL) necessitating the use of DMSO as a solvent in biological assays (MIC and time-kill 
curves) (12). This led us to investigate the use of delivery systems to try to improve PPA148 
solubility and thus bioavailability and efficacy. 
When considering suitable vehicles for the delivery of antimicrobials, liposomes represent an 
attractive option, having been successfully used as carriers for antifungal (AmBisome®, Abelet® 
and Amphotec®) and antibiotic (TOVI® Podhaler and Bethkis®) delivery to enhance efficiency 
and stability (59). Cyclodextrins, on the other hand, although widely used for drug solubilization 
through inclusion complex formation, in particular with the antifungal itraconazole (Sporanox®), 
are not currently used in commercial antibiotic products. Nevertheless, some studies on the 
antimicrobial activity of cyclodextrins have reported both an improvement of drug solubility (60) 
and permeability into cell membranes (16). The combination of both components, liposomes and 
cyclodextrins, offers a superior formulation which, to our knowledge, has not yet been investigated 
on antibiotic delivery. This research suggests that ACL offers improved stability of liposomes in 
the presence of cyclodextrins, suppresses the concentration and competitive effect on the 
dissociation of drug/CD complex and finally provides specificity to bacterial cells through Ca2+ 
bridges between the fluidosomes and the bacterial envelope. 
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In this study, β-cyclodextrin derivatives, HPβCD and RAMEB, were successfully used to improve 
the solubility of PPA148, up to approximately 50 g/mL and 90 g/mL, respectively, forming a 
1:2 complex. PPA148 presented a higher affinity towards RAMEB compared to HPβCD, which is 
attributed to the hydrophobic microenvironment provided by the methyl substitution (61); this 
derivative was thus taken forward for combination with liposomes. The RAMEB/PPA148 
complex was incorporated into fluid liposomes (DPPC/DMPG of 18/1) with an encapsulation 
efficiency of 67  11% and drug loading of 5  1%.  
The in vitro Kirby Bauer assay revealed an increased efficacy of the novel antibiotic formulated 
in cyclodextrins compared to non-formulated drug against E. coli DH5α. RAMEB alone did not 
lead to bacterial growth inhibition, showing that it may work as a permeability enhancer to increase 
drug update by Gram-negative bacteria. Previous work has also reported increased drug potency 
against Gram-negative bacteria by using inclusion complexes of β-lactam antibiotics with different 
types of cyclodextrins (62). While the mechanism of action of cyclodextrins has not yet been 
clarified, it has been reported that β-CD may drive the internalization of the β-CD-antibiotic 
complex via (i) enhanced adhesion to the bacterial surface with local release of the antibiotic, and 
(ii) destabilization of the bacterial envelope (62–64). The former behavior was evidenced in this 
study by examining the interfacial adsorption of RAMEB on model IM monolayers. The efficacy 
of PPA148-in-RAMEB-in-fluidosome was not statistically different from that of the 
PPA148/RAMEB complex. Nevertheless, fluidosomes offer specificity to the Gram negative 
bacterial membrane, as shown by the interfacial studies, and may protect the complex from 
dissolution and dissociation (65), thus preventing a possible reduction in bioavailability during 
delivery.  In addition, the entrapment of the water-soluble inclusion complex into fluidosomes led 
to the accommodation of the insoluble PPA148 in the aqueous phase of the vesicles. It is worth 
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noting that PPA148-in-RAMEB-in-fluidosome (1 μg PPA148), showed equivalent efficacy to pure 
rifampicin (30 μg).  
The interactions between PPA148, cyclodextrins and fluidosomes with model bacterial 
membranes were measured using interfacial techniques. The Gram-negative bacterial envelope 
consists in part of two permeability barriers, the first being the LPS-containing asymmetric OM, 
and the second being phospholipid-containing IM, separated by the peptidoglycan-containing 
periplasm. In the monolayer studies, Rc J5 LPS extracted from E. coli and Lipid A extracted from 
the Re R595 S. minnesota were used to mimic the outer leaflet of the OM and to examine the steric 
hindrance created by the presence of the core oligosaccharide chain in the former. A mixture of 
DPPC/DPPG was used to mimic the IM. Fluidosomes were tested against model OM as it is the 
carrier of the drug/CD complex and is proposed to release its payload in the cytoplasmic space, 
while cyclodextrin was tested against model IM as it is incorporated in the liposomes and is 
suggested to enhance the transport of PPA148 through the cytoplasmic barrier (IM). PPA148 was 
tested against both the outer and inner model membranes. 
The Gibbs isotherms provided useful insights into the molecular interactions of the drug, RAMEB 
and HPβCD on phospholipid monolayers, either at the level of the polar region when they are in 
contact with the IM of the cell envelope, or at the level of the hydrophobic domain of the lipid 
bilayer. Although PPA148 adsorbs strongly at the bare interface, its adsorption at the lipid/air 
interface is weaker, which reflects the effect of steric hindrance from the lipids. Between the two 
lipid monolayers tested, the interaction of PPA148 with model IM shows a higher affinity towards 
the DPPC/DPPG monolayer than the model outer leaflet of the OM. This could be attributed to 
the smaller headgroup of DPPC/DPPG, leading to a weak steric hindrance to PPA148 and a 
stronger interaction. PPA148 showed a weak interaction with Rc J5 LPS and R595 Lipid A. 
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Interestingly, the adsorption of PPA148 in the R595 Lipid A, which lacks the core oligosaccharide, 
caused a larger change in surface pressure than with Rc J5 LPS. This suggests that the core 
polysaccharide region of the Rc J5 LPS creates a steric barrier, hindering the interfacial adsorption 
of PPA148. The high affinity of PPA148 with lipid A reflects the effect of steric hindrance on 
drug’s interaction with model lipid membranes and confirms the need of a formulation to 
overcome the limited permeation of both barriers. 
PPA148 and rifampicin present a different interaction profile with both model OM and IM 
monolayers. The findings for rifampicin, that it was attracted to the phospholipid monolayer 
(DPPC/DPPG [3/1]) partially but did not interact with model OM, are in agreement with its 
mechanism of transport: it does not partition in the OM but it partitions in DPPC monolayers via 
electrostatic attraction with the headgroups of DPPC in an acidic environment (pH=5) (66). 
PPA148 cannot be ionized and thus the Gibbs isotherm in model IM reveals a weaker but faster 
interaction compared to rifampicin, possibly due to the absence of ionic bonds. It is suggested that 
PPA148 is likely to enter the cell via diffusion through the membrane due to its high 
hydrophobicity. However, its diffusion is hindered by the steric effect of LPS. 
The interaction of HPβCD and RAMEB with phospholipid monolayers suggest a lipid-solubilizing 
effect of model IM monolayers, whereas little effect was found for the model OM monolayers. It 
was found that upon cyclodextrin-membrane interaction, the type of βCD derivative affects the 
efficiency of the interaction with DPPC/DPPG monolayer, with HPβCD showing a weaker 
interaction. RAMEB shows a high affinity towards the DPPC/DPPG monolayer, which was 
expected because RAMEB has been reported to induce phospholipid exchange more efficiently 
than HPβCD (67). In addition, it has also been reported that RAMEB forms soluble complexes 
with DPPC (68), which explains the negative surface pressure of the isotherm. It is proposed that 
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RAMEB interacts with the phospholipids of the IM without causing any defects on the membrane 
while releasing PPA148 in the cytoplasm, in which the intracellular target is located. 
The fluidosomes presented different interaction profiles in the presence and absence of steric 
hindrance. The air/liquid interface monolayer interaction experiment revealed adsorption of 
material on a lipid free surface and the R595 Lipid A monolayer, while lipid solubilization took 
place with the Rc J5 LPS monolayer. It has been reported that the aggregation and fusion of 
fluidosomes with Gram-negative bacterial membrane is promoted by the presence of Ca2+ or other 
divalent cations by inducing the neutralization of the negatively charged Lipid A and dehydration 
of phospholipids of the membrane (22). It has been found that LPS becomes exposed to 
fluidosomes in the presence of divalent cations by changing the orientation of its oligosaccharide 
chains, which become parallel with the interface (22). These results suggest that fluidosomes 
composed of DPPC/DMPG [18/1] could release their content by fusion into the OM membrane, 
as also found with a DPPC/DMPG [9/1] system by negative staining and lipid mixing assay with 
fluorescence probes (22). This bridging by Ca2+ ions between the bacterial envelope and 
fluidosomes may also constitute a means of ensuring specificity of the delivery system to bacterial 
cells. 
To complement these monolayer studies and further investigate the putative fluidosome fusion 
mechanism, a model Gram-negative bacterial asymmetric membrane consisting of Ra LPS and 
DPPC as the outer and inner leaflet of the OM was used to examine the interaction between the 
liposomal carrier and the OM (44,47,49). Neutron reflectivity (NR) was used to characterize the 
structural changes in this model membrane when placed in contact with the formulation. The 
challenge of the model OM by fluidosomes caused an increase of hydrogenous material in the 
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inner leaflet and an increase of deuterated material in the outer leaflet, which reveal the occurrence 
of lipid mixing within the membrane.  
Moreover, the formation of an additional curved bilayer associated with the deposited membrane 
was observed after a challenge by the fluidosomes. It has been reported that cations (Ca2+, Mg2+) 
trigger the fusion of liposomes in bacterial membranes through bridging of the layers between the 
outer leaflets of the membrane and liposome at the contact site (Figure 10) (22). It has been 
reported that Ca2+ are able to keep fluidosomes attached to the model membrane by creating local 
packing defects on the outer leaflet of both liposomes and LPS (Figure 10) accompanied by local 
dehydration (22), as observed by a decrease in the percentage of water of the Ra LPS headgroup. 
This strengthens evidence obtained from the monolayer studies for a possible mechanism of 
fluidosomes specificity to the bacterial envelope. Moreover, fluidosomes composed of 
DPPC/DMPG [18/1] tend to become more fluid around 38°C (Tm of 35°C) which also aids their 
fusion with the bacterial OM (23) (22).  
The findings reveal that ACL shows the potential to target both the outer and the inner membrane 
by combining two delivery systems in one carrier. Theoretically, fusion of fluidosomes with the 
OM facilitate the release of its core content (RAMEB/PPA148 complex) into the periplasm. 
RAMEB, in addition to increasing drug’s water solubility, would then be able to potentiate the 
transport of PPA148 to effect penetration of the antibiotic through the IM (phospholipid bilayer), 
without causing any damage to the membrane and thus allowing PPA148 to reach its intracellular 
target. NR showed that fusion of fluidosomes is created by a bridge layer between the outer leaflets 
of the membrane (LPS) and liposomes (DPPC/DMPG [18/1]) in the presence of Ca2+, while 
microbiological and interaction studies showed that RAMEB improves the adhesion to bacterial 
surface and drug’s transport through phospholipid layers without causing any damage to the 
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membrane. From a biophysical point of view, each compartment of the formulation was tested 
separately to investigate the putative mechanism of action. However, there is a need for future 
investigation on drug/RAMEB complex and ACL interaction with model bacterial membranes to 
achieve a complete picture of the proposed mechanism.  
6 CONCLUSION 
This work is the first report of an antibiotic-in-cyclodextrin-in-liposome (ACL) formulation using 
the novel hydrophobic antimicrobial agent PPA148, which shows promising activity against 
Gram-negative bacteria. The water solubility of the drug was enhanced by interaction with two 
modified β-cyclodextrins, HPβCD and RAMEB. Although ACL did not present significant 
difference in inhibition of bacteria compared to the drug/CD complex itself, it interacts with both 
the OM and IM of bacterial envelope and its proposed mechanism of action was examined at the 
molecular level, using interfacial techniques. Our results suggest that fluidosomes act as carriers 
of the complex, fusing into the OM and thus facilitating the release of their payload, while RAMEB 
also enables transport through the IM. Neutron reflectivity were successfully used to demonstrate 
the possible envelope-breaching mechanism of fluidosomes upon interaction with the model OM.  
The molecular understanding of ACL provided in this work demonstrate their promise as 
hydrophobic antimicrobial agents, either new drugs, or those that have become ineffective due to 
antimicrobial resistance. ACL formulations may contribute to the fight against AMR because they 
target both the OM and IM of Gram-negative bacteria, while enhancing the solubility of drugs and 





Table of physicochemical properties of PPA148 and best fit parameter values with 95% confidence 
interval for the NR fits. 
Figures of absorbance of increasing PPA148 concentration, effect of increasing concentration of 
PPA148 on particle size when the drug is in H2O and HPCD, 1H NMR spectra used to plot Job’s 
plot, intensity distribution of empty DPPC/DMPG (18/1) liposomes in HEPES buffered saline (pH 
7.2), linear calibration curve of the area under the curve (AUC) of PPA148, fluidosome stability, 
adsorption of PPA148 at the air/liquid interface, Gibs isotherms of cyclodextrins and model OM 
monolayers, Langmuir trough isotherm cycles for the NR preparation of model membranes and 
posterior distributions for all the layers of the NR systems. 
Equations used in the quantification of Stewart assay to quantify and calculate the DPPC 
concentration. 
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